RZLT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RZ

Mkt Cap

$344.8M

Volume

1.27M

Next Earnings

November 5th

Loading chart

RZ

RZLTRezolute, Inc. Common Stock (NV)

RZLT

Pay with—

Available Balance0.00

RZ

Mkt Cap

$377.2M

Volume

1.27M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Rezolute to Participate in Upcoming Investor ConferencesRezolute, Inc., a rare disease company focused on treating hyperinsulinism, announced it will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference (May 19, 2026) and the Jefferies Global Healthcare Conference (June 2-4, 2026). The company will present oral results from its Phase 3 sunRIZE study of ersodetug in patients with congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting, including previously announced topline results and additional continuous glucose monitoring-based outcomes showing significant improvements in glycemic control.GlobeNewswire Inc. · May 11, 2026

Rezolute, Inc. Investigated by the Portnoy Law FirmRezolute, Inc. (NASDAQ: RZLT) experienced a severe stock price collapse of 87.2% on December 19, 2025, following the announcement that its lead drug candidate ersodetug failed to meet primary and key secondary endpoints in the Phase 3 sunRIZE clinical trial for congenital hyperinsulinism. The drug failed to demonstrate statistically significant efficacy over placebo, prompting a securities fraud investigation by the Portnoy Law Firm.GlobeNewswire Inc. · Apr 24, 2026

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business AchievementsXOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.GlobeNewswire Inc. · Mar 18, 2026

Rezolute to Participate in the Citizens Life Sciences ConferenceRezolute, Inc., a late-stage rare disease company developing ersodetug antibody therapy for hyperinsulinism-induced hypoglycemia, announced it will participate in the Citizens Life Sciences Conference on March 10-11, 2026, in Miami, FL, with management available for one-on-one investor meetings.GlobeNewswire Inc. · Mar 4, 2026

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman InvestigatingRezolute, Inc. (NASDAQ: RZLT) experienced a dramatic 90% intraday stock price decline on December 11, 2025, after announcing that its Phase 3 sunRIZE trial for ersodetug failed to meet primary and secondary endpoints for treating hypoglycemia caused by hyperinsulinism. The failure contradicted the company's previous assurances about the drug's efficacy and market potential, prompting shareholder rights firm Hagens Berman to investigate potential investor fraud.GlobeNewswire Inc. · Feb 9, 2026

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026Rezolute's Phase 3 sunRIZE study in congenital hyperinsulinism failed to meet its primary and key secondary endpoints. While the top dose of ersodetug (10 mg/kg) showed a 45% reduction in hypoglycemia events compared to 40% in the placebo arm, this marginal difference represents a study failure. The company plans to meet with the FDA regarding the path forward.GlobeNewswire Inc. · Feb 4, 2026

SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteRezolute's stock plummeted on December 11, 2025, following disappointing results from its Phase 3 sunRIZE clinical trial for ersodetug. The trial failed to meet both primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events versus placebo. Securities law firm Faruqi & Faruqi is investigating potential claims on behalf of affected investors.GlobeNewswire Inc. · Feb 4, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMAPomerantz LLP is investigating potential securities fraud claims against XOMA Royalty Corporation following a significant stock price decline. The investigation was triggered by disappointing Phase 3 trial results from development partner Rezolute for the drug ersodetug, which failed to meet primary and secondary endpoints in treating congenital hyperinsulinism. XOMA's stock fell 22.76% on the news.GlobeNewswire Inc. · Jan 20, 2026

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLTRezolute, Inc. shares collapsed approximately 85-90% on December 11, 2025, after the company's Phase 3 sunRIZE clinical trial for its lead drug candidate ersodetug failed to meet primary and key secondary endpoints in treating congenital hyperinsulinism. The stock dropped from around $10.94 to an intraday low near $0.90, triggering Nasdaq volatility halts.GlobeNewswire Inc. · Jan 3, 2026

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteRezolute's stock plummeted on December 11, 2025, following disappointing results from its Phase 3 sunRIZE clinical trial for ersodetug, a lead drug candidate for congenital hyperinsulinism. The study failed to meet its primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events versus placebo. Securities law firm Faruqi & Faruqi is investigating potential claims against the company on behalf of affected investors.GlobeNewswire Inc. · Dec 24, 2025

to start trading

RZ

RZLTRezolute, Inc. Common Stock (NV)

RZLT

Pay with—

Available Balance0.00

Your PositionYou don't own any RZLT yet.

Related Tickers

Earnings